Durect gains $8M on positive pain drug data
Durect, a drug delivery tech developer, says that it is gaining an $8 million milestone payment after a mid-stage clinical trial for the postoperative pain drug Posidur delivered promising data. Researchers said that the drug reduced pain and the demand for supplemental opioids. Developers will now talk to the FDA about designing a Phase III trial for the drug. The news helped buoy Durect's stock price.
- see the release
- check out the AP report
Related Articles:
Durect soars on $202M pact and new trial data. Report
Voyager tells Durect that it's ending Memryte trial early. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
